Hong-yu Li, PhD

Full Member

Research Program:

Cancer Therapeutics

Faculty Rank:

Professor

Campus:

University of Arkansas for Medical Sciences

College:

College of Pharmacy

Department:

Pharmaceutical Sciences

Cancer Research Interest

Disease Site Focus: Brain, Breast, Cutaneous/Melanoma, GI, Head and Neck, Leukemia/ Lymphoma, Multiple Myeloma, Thoracic/ Lung
Research Focus Area: Treatment
Type of Research: Basic

Contact Information

Email Address: HLI2@UAMS.EDU
Profiles Research Networking Software: View Profile

Active Grants

NIH/Nat. Cancer Institute – R01CA249282
“Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance”
Principal Investigator
12/15/20 – 12/15/25

Publications

Chen J, Wang Z, Phuc T, [et al., including Li HY]. Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. PLoS pathogens. 2023 19(1):e1011089. PMID: 36638143. PMCID: PMC9879403.
Yan W, Pan BS, Shao J, [et al., including Li HY]. Feasible Column Chromatography-Free, Multi-Gram Scale Synthetic Process of VH032 Amine, Which Could Enable Rapid PROTAC Library Construction. ACS omega. 2022 7(30):26015-26020. PMID: 35936457. PMCID: PMC9352171.
Yan Y, Shao J, Ding D, [et al., including Li HY]. 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O'PROTAC. Chemical communications (Cambridge, England). 2022 58(14):2383-2386. PMID: 35080528.
Zhang L, Moccia M, Briggs DC, [et al., including Li HY]. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. Journal of medicinal chemistry. 2022 65(2):1536-1551. PMID: 35081714.
Shao J, Yan Y, Ding D, [et al., including Li HY]. Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2021 8(20):e2102555. PMID: 34397171. PMCID: PMC8529430.
Hsu CC, Zhang X, Wang G, [et al., including Li HY]. Inositol serves as a natural inhibitor of mitochondrial fission by directly targeting AMPK. Molecular cell. 2021 81(18):3803-3819.e7. PMID: 34547240. PMCID: PMC8462099.
Zhang L, Lakkaniga NR, Bharate JB, [et al., including Li HY]. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. European journal of medicinal chemistry. 2021 225:113776. PMID: 34479037.
Kharbanda A, Tran P, Zhang L, [et al., including Li HY]. Discovery of 4-aminoquinolines as highly selective TGF?R1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology. European journal of medicinal chemistry. 2021 225:113763. PMID: 34419892.
Moccia M, Yang D, Lakkaniga NR, [et al., including Li HY]. Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases. Scientific reports. 2021 11(1):16103. PMID: 34373541. PMCID: PMC8352932.
Kharbanda A, Zhang L, Saha D, [et al., including Li HY]. Discovery and biological evaluation of phthalazines as novel non-kinase TGF? pathway inhibitors. European journal of medicinal chemistry. 2021 223:113660. PMID: 34246853.
Fan H, Guo Y, Tsai YH, [et al., including Li H]. A conserved BAH module within mammalian BAHD1 connects H3K27me3 to Polycomb gene silencing. Nucleic acids research. 2021 49(8):4441-4455. PMID: 33823544. PMCID: PMC8096256.
Yan W, Zhang L, Lv F, [et al., including Li HY]. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. European journal of medicinal chemistry. 2021 216:113265. PMID: 33652352.
Zhu X, Wang X, Yan W, [et al., including Li HY]. Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response. NAR cancer. 2021 3(1):zcab010. PMID: 33778494. PMCID: PMC7984809.
Cai Z, Moten A, Peng D, [et al., including Li HY]. The Skp2 Pathway: A Critical Target for Cancer Therapy. Seminars in cancer biology. 2020 67(Pt 2):16-33. PMID: 32014608.
Wang J, Cheng P, Pavlyukov MS, [et al., including Li H]. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. The Journal of clinical investigation. 2020. PMID: 33044225.
Qu CH, Song GT, Tang DY, [et al., including Li HY]. Microwave-Assisted Copper Catalysis of ?-Difluorinated gem-Diol toward Difluoroalkyl Radical for Hydrodifluoroalkylation of para-Quinone Methides. The Journal of organic chemistry. 2020 85(19):12785-12796. PMID: 32847359.
Lakkaniga NR, Zhang L, Belachew B, [et al., including Li HY]. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. European journal of medicinal chemistry. 2020 203:112589. PMID: 32717530.
Yan W, Lakkaniga NR, Carlomagno F, [et al., including Li HY]. Correction to Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. Journal of medicinal chemistry. 2020 63(17):10089. PMID: 32841014.
Wang J, Cheng P, Pavlyukov MS, [et al., including Li H]. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. The Journal of clinical investigation. 2020 130(9):5027. PMID: 32870163. PMCID: PMC7456217.
Lakkaniga NR, Gunaganti N, Zhang L, [et al., including Li HY]. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. European journal of medicinal chemistry. 2020 206:112691. PMID: 32823007.
Xu J, Tan HB, Zhang YJ, [et al., including Li HY]. Catalyst-Free One-Pot Synthesis of Densely Substituted Pyrazole-Pyrazines as Anti-Colorectal Cancer Agents. Scientific reports. 2020 10(1):9281. PMID: 32518332. PMCID: PMC7283261.
Moccia M, Frett B, Zhang L, [et al., including Li HY]. Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology. Journal of medicinal chemistry. 2020 63(9):4506-4516. PMID: 32298114.
Storey AJ, Naceanceno KS, Lan RS, [et al., including Li HY]. ProteoViz: a tool for the analysis and interactive visualization of phosphoproteomics data. Molecular omics. 2020. PMID: 32347222.
Lei J, Song GT, He LJ, [et al., including Li HY]. One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. Chemical communications (Cambridge, England). 2020 56(14):2194-2197. PMID: 31971170.
Lei J, Song GT, He LJ, [et al., including Li HY]. Correction: One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. Chemical communications (Cambridge, England). 2020 56(14):2210. PMID: 32031562.
Saha D, Kharbanda A, Yan W, [et al., including Li HY]. The Exploration of Chirality for Improved Druggability within the Human Kinome. Journal of medicinal chemistry. 2020 63(2):441-469. PMID: 31550151.
Lakkaniga NR, Boerma M, Balasubramaniam M, [et al., including Li HY]. Structural Characterization of the Aurora Kinase B "DFG-flip" Using Metadynamics. The AAPS journal. 2019 22(1):14. PMID: 31853739.
Qu CH, Song GT, Xu J, [et al., including Li HY]. Merging Visible Light with Cross-Coupling: The Photochemical Direct C-H Difluoroalkylation of Imidazopyridines. Organic letters. 2019 21(20):8169-8173. PMID: 31430159.
Li Y, Huang JH, Song GT, [et al., including Li HY]. Diversity-Oriented Synthesis of Imidazo-Dipyridines with Anticancer Activity via the Groebke-Blackburn-Bienaymé and TBAB-Mediated Cascade Reaction in One Pot. The Journal of organic chemistry. 2019 84(19):12632-12638. PMID: 31357859.
Lewis GD, Li HK, Quan EM, [et al.]. The Role of Eye Plaque Brachytherapy and MR Imaging in the Management of Diffuse Choroidal Hemangioma: An Illustrative Case Report and Literature Review. Practical radiation oncology. 2019 9(5):e452-e456. PMID: 31128304.
Zhang W, Wang G, Xu ZG, [et al., including Li HY]. Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS. Cell. 2019 178(1):176-189.e15. PMID: 31155231. PMCID: PMC6625351.
Yan W, Lakkaniga NR, Carlomagno F, [et al., including Li HY]. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. Journal of medicinal chemistry. 2019 62(4):1731-1760. PMID: 30188734.
Chen ZZ, Li SQ, Zhang YJ, [et al., including Li HY]. Synthesis of Pyridodiindoles with Anticancer Activity by a Three-Component Cascade Condensation. Organic letters. 2018 20(24):7811-7815. PMID: 30512962.
Gunaganti N, Kharbanda A, Lakkaniga NR, [et al., including Li HY]. Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts. Chemical communications (Cambridge, England). 2018 54(92):12954-12957. PMID: 30375586. PMCID: PMC6284400.
Frett B, McConnell N, Kharbanda A, [et al., including Li HY]. Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-a]pyridine derivatives. Tetrahedron. 2018 74(35):4592-4600. PMID: 30344351. PMCID: PMC6192254.
He LJ, Yang DL, Li SQ, [et al., including Li HY]. Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells. Bioorganic & medicinal chemistry. 2018 26(14):3899-3908. PMID: 29921474. PMCID: PMC6718200.
Li HY, Roy K. Molecular diversity: at a crossroads. Molecular diversity. 2018 22(3):543. PMID: 30030780.
Pierson SK, Stonestrom AJ, Shilling D, [et al., including Li H]. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. American journal of hematology. 2018 93(7):902-912. PMID: 29675946.
Lei J, Xu ZG, Tang DY, [et al., including Li HY]. Acid-Promoted One-Pot Synthesis of Substituted Furan and 6-Methylpyrazin-2(1 H)-one Derivatives via Allene Intermediate Formed in Situ. ACS combinatorial science. 2018 20(5):292-297. PMID: 29620860.
Xu ZG, Li SQ, Meng JP, [et al., including Li HY]. Functionalized Spiroindolines with Anticancer Activity through a Metal-Free Post-Ugi Diastereoselective One-Pot Cascade Reaction. Chemistry (Weinheim an der Bergstrasse, Germany). 2018 24(26):6732-6736. PMID: 29676029. PMCID: PMC6042644.
Bharate JB, McConnell N, Naresh G, [et al., including Li HY]. Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. Scientific reports. 2018 8(1):3722. PMID: 29487300. PMCID: PMC5829162.
McConnell N, Frett B, Li H. Microwave-assisted green synthesis of anilines, phenols, and benzenediamines without transition metals, ligands, or organic solvents. Green chemistry letters and reviews. 2018 11(3):286-295. PMID: 30984284. PMCID: PMC6457683.
McConnell N, Xu Z, Kumarasamy V, [et al., including Li HY]. Synthesis of Constrained Heterocycles Employing Two Post-Ugi Cyclization Methods for Rapid Library Generation with In Cellulo Activity. ChemistrySelect. 2017 2(35):11821-11825. PMID: 30140731. PMCID: PMC6103208.
Wang J, Cheng P, Pavlyukov MS, [et al., including Li H]. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. The Journal of clinical investigation. 2017 127(8):3075-3089. PMID: 28737508. PMCID: PMC5531394.
De Falco V, Carlomagno F, Li HY, Santoro M. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best practice & research. Clinical endocrinology & metabolism. 2017 31(3):307-318. PMID: 28911727. PMCID: PMC5624797.
Xi JB, Fang YF, Frett B, [et al., including Li HY]. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. European journal of medicinal chemistry. 2017 126:1083-1106. PMID: 28039836.